The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders: * Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
85
intense pulsed light (IPL) using the Medical Device Anthelia
CH Auxerre
Auxerre, France
RECRUITINGHIACT Brest
Brest, France
RECRUITINGCentre TrialAzur
Nice, France
RECRUITINGCH Périgueux
Périgueux, France
NOT_YET_RECRUITINGCHU POitiers
Poitiers, France
RECRUITINGEfficacity for Excessive Hairiness:
Excessive Hairiness by hair counting a 4cm2 surface (To demonstrate a hair reduction of 50% between the average score of the treated aera before and after a cycle of treatment defined as six sessions spaced by 12 weeks)
Time frame: up to 18 months
Efficacity for Vascular lesions and Pigmented lesions
Vascular lesions: To demonstrate a reduction of 70% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 4 weeks. To demonstrate a clinical improvement of 50% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 4 weeks. Pigmented Lesions: To demonstrate a reduction of 60% between the average score of the treated aera before and after a cycle of treatment defined as three sessions spaced by 10 weeks.
Time frame: up to 4 months
Efficacity for Acne vulgaris
measuring the diameter of each pimple in a treated area (before and after), To demonstrate a lesion reduction of 50% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 2 weeks.
Time frame: up to 4 months
For all patients decrease of the IRBMS score
IRBMS (Rosenberg Self-Esteem Scale), minimum score is 10, maximum score is 40
Time frame: 4 to 18 months
- For all patients decrease of the DLQI score
DLQI (Dermatology Life Quality Index), minimum score is 0, maximum score is 30
Time frame: 4 to 18 months
For only Acne patients, at least 20% reduction in the ECLA score
ECLA ("Echelle de Cotation des Lésions d'Acné" or Acne Lesion Score Scale), minimum score is 0, maximum score is 36
Time frame: 4 to 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.